Kalra, J., Warburton, C., Fang, K., Edwards, L., Daynard, T., Waterhouse, D., . . . Bally, M. (2009). QLT0267, a small molecule inhibitor targeting integrin-linked kinase (ILK), and docetaxel can combine to produce synergistic interactions linked to enhanced cytotoxicity, reductions in P-AKT levels, altered F-actin architecture and improved treatment outcomes in an orthotopic breast cancer model. BioMed Central.
Styl cytowania ChicagoKalra, Jessica, et al. QLT0267, a Small Molecule Inhibitor Targeting Integrin-linked Kinase (ILK), and Docetaxel Can Combine to Produce Synergistic Interactions Linked to Enhanced Cytotoxicity, Reductions in P-AKT Levels, Altered F-actin Architecture and Improved Treatment Outcomes in an Orthotopic Breast Cancer Model. BioMed Central, 2009.
Styl cytowania MLAKalra, Jessica, et al. QLT0267, a Small Molecule Inhibitor Targeting Integrin-linked Kinase (ILK), and Docetaxel Can Combine to Produce Synergistic Interactions Linked to Enhanced Cytotoxicity, Reductions in P-AKT Levels, Altered F-actin Architecture and Improved Treatment Outcomes in an Orthotopic Breast Cancer Model. BioMed Central, 2009.